Kings Path Partners’s ADMA Biologics ADMA Stock Holding History

Kings Path Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Hold	28,940	–	–	0.06%	105
2026 Q1	$528K	Hold	28,940	–	–	0.19%	49
2025 Q4	$528K	Hold	28,940	–	–	0.19%	49
2025 Q3	$424K	Hold	28,940	–	–	0.16%	69
2025 Q2	$527K	Buy	28,940 +7,515	+35%	+$153K	0.21%	54
2025 Q1	$425K	Buy	+21,425	New	+$371K	0.21%	62

Other funds holding ADMA

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Kings Path Partners's ADMA Position: Q2 2026 in Review

Kings Path Partners held its ADMA Biologics (ADMA) position steady in Q2 2026 at 28,940 shares worth $242K. The position accounts for 0.06% of the portfolio, ranked #105.

Kings Path Partners first reported a position in ADMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $528K in Q1 2026. 41 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Kings Path Partners held 28,940 shares of ADMA Biologics worth $242K as of Q2 2026.
Kings Path Partners left its ADMA Biologics share count unchanged in Q2 2026.
ADMA Biologics made up 0.06% of Kings Path Partners's portfolio in Q2 2026, its #105 holding.
Kings Path Partners first reported a position in ADMA Biologics in Q1 2025 and has held it in 6 quarters since.
Kings Path Partners's ADMA Biologics position peaked at $528K in Q1 2026.
41 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Kings Path Partners's 13F filing for Q2 2026, filed 14 Jul 2026.